A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients with Metastatic Castration-Resistant Prostate Cancer
Clinical Trial Grant
Awarded By
Fibrogen, Inc.
Start Date
October 23, 2025
End Date
October 22, 2030
Awarded By
Fibrogen, Inc.
Start Date
October 23, 2025
End Date
October 22, 2030